Medios AG (ILM1) - Total Liabilities

Latest as of March 2026: €398.53 Million EUR ≈ $465.92 Million USD

Based on the latest financial reports, Medios AG (ILM1) has total liabilities worth €398.53 Million EUR (≈ $465.92 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Medios AG - Total Liabilities Trend (2009–2025)

This chart illustrates how Medios AG's total liabilities have evolved over time, based on quarterly financial data. See ILM1 working capital efficiency to evaluate short-term liquidity relative to the company's equity base.

Medios AG Competitors by Total Liabilities

The table below lists competitors of Medios AG ranked by their total liabilities.

Company Country Total Liabilities
BMTC Group Inc
TO:GBT
Canada CA$169.25 Million
Vodafone Group PLC
LSE:VOD
UK GBX75.52 Billion
Shenzhen Sine Electric Co. Ltd. A
SHG:688395
China CN¥164.89 Million
Precious Shipping Public Company Limited
BK:PSL-R
Thailand ฿9.21 Billion
D-Link Corp
TW:2332
Taiwan NT$5.07 Billion
Omega Flex Inc
NASDAQ:OFLX
USA $18.69 Million
Reconnaissance Energy Africa Ltd
V:RECO
Canada CA$4.67 Million
Corem Property Group AB (publ)
ST:CORE-PREF
Sweden Skr38.77 Billion

Liability Composition Analysis (2009–2025)

This chart breaks down Medios AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ILM1 market cap overview.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.92 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.77 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.43 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Medios AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Medios AG (2009–2025)

The table below shows the annual total liabilities of Medios AG from 2009 to 2025.

Year Total Liabilities Change
2025-12-31 €388.82 Million
≈ $454.57 Million
-8.33%
2024-12-31 €424.17 Million
≈ $495.89 Million
+236.78%
2023-12-31 €125.95 Million
≈ $147.24 Million
-1.54%
2022-12-31 €127.91 Million
≈ $149.54 Million
-1.59%
2021-12-31 €129.98 Million
≈ $151.96 Million
+149.42%
2020-12-31 €52.11 Million
≈ $60.92 Million
+49.14%
2019-12-31 €34.94 Million
≈ $40.85 Million
+25.15%
2018-12-31 €27.92 Million
≈ $32.64 Million
+74.17%
2017-12-31 €16.03 Million
≈ $18.74 Million
+16.48%
2016-12-31 €13.76 Million
≈ $16.09 Million
+7321.68%
2015-12-31 €185.43K
≈ $216.79K
+106.53%
2014-12-31 €89.78K
≈ $104.97K
-60.37%
2013-12-31 €226.54K
≈ $264.85K
-15.52%
2012-12-31 €268.14K
≈ $313.49K
-4.48%
2011-12-31 €280.72K
≈ $328.20K
-45.84%
2010-12-31 €518.32K
≈ $605.98K
-117.75%
2009-12-31 €-2.92 Million
≈ $-3.41 Million
--

About Medios AG

XETRA:ILM1 Germany Medical Distribution
Market Cap
$376.91 Million
€322.39 Million EUR
Market Cap Rank
#14737 Global
#1458 in Germany
Share Price
€12.64
Change (1 day)
+1.28%
52-Week Range
€11.28 - €17.32
All Time High
€40.95
About

Medios AG, together with its subsidiaries, supplies specialty pharmaceutical drugs primarily in Germany. It operates through three segments: Patient-Specific Therapies; International Business; and Pharmaceutical Supply. The Patient-Specific Therapies segment manufactures medications for patients on behalf of pharmacies. This segment also includes cytostatic preparations, antibody therapies, and p… Read more